You are not currently logged in.
Access your personal account or get JSTOR access through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Converting-Enzyme Inhibitor Enalapril (MK421) In Treatment Of Hypertension With Renal Artery Stenosis
G. P. Hodsman, J. J. Brown, D. L. Davies, R. Fraser, A. F. Lever, J. J. Morton, G. D. Murray and J. I. S. Robertson
British Medical Journal (Clinical Research Edition)
Vol. 285, No. 6356 (Dec. 11, 1982), pp. 1697-1699
Published by: BMJ
Stable URL: http://www.jstor.org/stable/29508993
Page Count: 3
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Enalapril maleate (MK421), a new inhibitor of angiotensin converting enzyme, in single daily doses of 1.25-40 mg was assessed in five patients with hypertension and renal artery stenosis. Only small falls in plasma angiotensin II concentrations were seen at doses less than 10 mg; even with 10 and 20 mg, angiotensin II concentrations had risen again 24 hours from the last dose. During long-term treatment with 10-40 mg daily all patients achieved good blood-pressure control. No significant changes of body sodium or potassium values were seen. The drug was well tolerated with no serious side effects. These findings are evidence of the efficacy and acceptability of enalapril in the medical management of hypertension with renal artery stenosis.
British Medical Journal (Clinical Research Edition) © 1982 BMJ